InfuSystem Holdings Inc(INFU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 32.16 | EPS (ttm) | 0.41 | Insider Own | 5.58% | Shs Outstand | 19.9M | Perf Week | 6.93% |
| Market Cap | 0.26B | Forward P/E | 23.14 | EPS next Y | 23.19% | Insider Trans | 1.37% | Shs Float | 18.8M | Perf Month | 7.37% |
| Enterprise Value | 0.28B | PEG | 0.91 | EPS next Q | 0.13 | Inst Own | 77.46% | Short Float | 4.02% | Perf Quarter | 44.38% |
| Income | 0.01B | P/S | 1.82 | EPS this Y | 48.39% | Inst Trans | 5.63% | Short Ratio | 3.97 | Perf Half Y | 36.56% |
| Sales | 0.14B | P/B | 4.41 | EPS next 5Y | 25.31% | ROA | 8.61% | Short Interest | 0.75M | Perf YTD | 46.15% |
| Book/sh | 2.97 | P/C | 271.99 | EPS past 3/5Y | 632.25% -17.01% | ROE | 15.03% | 52W High | -0.3% ($13.15) | Perf Year | 25.94% |
| Cash/sh | 0.05 | P/FCF | 11.4 | Sales past 3/5Y | 9.28% 8.05% | ROIC | 10.37% | 52W Low | 79.84% ($7.29) | Perf 3Y | 30.84% |
| Dividend Est. | - | EV/EBITDA | 10.76 | EPS Y/Y TTM | 75.23% | Gross Margin | 56.05% | Volatility(W/M) | 3.69% 2.95% | Perf 5Y | 1.79% |
| Dividend TTM | - | EV/Sales | 1.98 | Sales Y/Y TTM | 2.47% | Oper. Margin | 9.26% | ATR (14) | 0.43 | Perf 10Y | 380.22% |
| Dividend Ex-Date | - | Quick Ratio | 2.14 | EPS Q/Q | 25.12% | Profit Margin | 5.96% | RSI (14) | 72.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.5 | Sales Q/Q | 2.59% | SMA20 | 6.79% ($12.28) | Beta | 1.5 | Target Price | $16.83 |
| Payout | - | Debt/Eq | 0.39 | Earnings | 2026/8/4 | SMA50 | 15.65% ($11.34) | Rel Volume | 0.86 | Prev Close | $12.8 |
| Employees | 473 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | 42.86% 1.6% | SMA200 | 35.27% ($9.69) | Avg Volume(3M) | 0.19M | Price | $13.11 |
| IPO | 2006/6/15 | Option/Short | Yes/Yes | Trades | 2448 | Volume | 163,864 | Change | 2.42% |
Company
INFU is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 InfuSystem Holdings is a US-based healthcare company that provides infusion pumps and medical device services in the areas of oncology, pain management, and wound care. The company operates two business segments: patient services and device solutions, and it is a niche leader in the medical device field with a high market share in the outpatient oncology infusion market in the United States and Canada.
Over the past 1 year, on the higher side
0% below its 1-year high.
INFU makes money exceptionally well
9.26% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.4% this year.
Tap to view numbers
But it is not cheap
Trading at 32.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +30.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 77.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
RUSC 0.00%
IWC 0.00%
AIMS 0.00%
QSML 0.00%
AVUV 0.00%It ranks #4 in the industry
Based on market cap of $261M.
INFU $261M PER 32.2
ABT $179B PER 33.5
MDT $116B PER 22.4
SYK $106B PER 28.5
FAQ
What kind of company is INFU?
INFU belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of INFU?
The market cap of INFU is approximately $261M, ranking 3,894 within its sector.
What is the P/E ratio of INFU?
INFU has a P/E ratio of approximately 32.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INFU?
INFU has recorded a 52-week high of $13.15 and a low of $7.29.
